12:00 AM
 | 
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISIS-SMNRx: Phase Ib/IIa started

Isis began an open-label, dose-escalation, U.S. Phase Ib/IIa trial to evaluate intrathecal injections of ISIS-SMNRx in about 24 patients ages 2-15 years. In January, Isis granted Biogen Idec an exclusive, worldwide option to develop and commercialize...

Read the full 156 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >